NCT Number: NCT02220556
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Institut Curie, Paris, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- 18 years old or more
- Performance status from 0 to 4
- Patient treated followed for histologically confirmed solid tumor type of any of these localization : breast, prostate, uterus, ovary, colon, lung, head and neck, melanoma.
- Informed consent form signed.
Exclusion criteria
- Patient with history of other invasive cancer within 5 years.
- Patient treated for any non-invasive cancer
- Patient individually deprived of liberty or placed under the authority of a tutor
- Geographical condition potentially preventing compliance with the study protocol.
Treatment and study plan
Primary outcomes
-
CTC, CEC or ctDNA incidence
Time frame: 3 years
number of CTC or CEC in 7.5ml of blood
Secondary outcomes
-
CTC and CEC molecular characterization
Time frame: 3 years
This outcome is self-explanatory.
-
Circulating tumor DNA (ctDNA) detection and quantification
Time frame: 3 years
plasma mutation detection (number of copy)
Sponsors and collaborators
Lead sponsor
Institut Curie
Other
Registry information
Acronym: CTC-CEC-ADN
Important dates
- Study start
- 2010
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Aug 20, 2014
- Registry last updated
- Aug 8, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
NCT06614140
Cancer, Neoplasms
Bangkok, Thailand
View Trial DetailsA Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
NCT05763004
Solid Tumor, Adult
Clayton, Australia
View Trial DetailsMolecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1
NCT05620472
Solid Tumor, Adult
Tomsk, Russia
View Trial DetailsStudy of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
NCT04552288
Hematologic Diseases, Hematologic Malignancy
Basking Ridge, New Jersey, United States
View Trial Details